Quinazolin-4(3H)-one NAMs for Selective mGlu2 Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack selective modulators for metabotropic glutamate receptor 2 (mGlu2), which are essential for treating diseases such as depression, anxiety, obsessive-compulsive disorder, cognitive disorders, Alzheimer's disease, and autism spectrum disorders, due to the high conservation of orthosteric binding sites across mGlu isoforms.
Innovation Solution
Development of negative allosteric modulators (NAMs) of mGlu2, specifically compounds of formula (I), which selectively inhibit mGlu2 activity by binding to allosteric sites, providing therapeutic benefits for disorders associated with mGlu2 dysfunction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If orthosteric binding sites are targeted for mGlu2 modulation, then therapeutic effects can be achieved, but selectivity is lost due to high conservation across mGlu isoforms
Solution Approach 1:
The patent introduces allosteric binding sites as intermediaries between the orthosteric glutamate binding site and the receptor's functional output. These allosteric sites, located in transmembrane domains (particularly TM2-TM3 and TM5-TM6 regions), serve as mediator regions that can be selectively targeted by modulators to achieve isoform-specific modulation without competing with glutamate at the conserved orthosteric site. The allosteric modulators bind to these intermediate regions to induce conformational changes that selectively affect mGlu2 function.
2Adaptability or versatility
If allosteric modulators are developed to achieve selectivity, then specificity for mGlu2 improves, but development complexity increases
Solution Approach 1:
The patent segments the mGlu2 receptor structure into functionally distinct regions: the conserved orthosteric binding site and the variable allosteric binding sites. By focusing drug development efforts on the allosteric segments (particularly in transmembrane domains), the patent reduces the search space for selective modulators. This segmentation allows medicinal chemists to design compounds that target specific structural features of mGlu2's allosteric sites rather than attempting to navigate the highly conserved orthosteric site.
Solution Approach 2:
The patent identifies specific local regions within the allosteric sites that exhibit mGlu2-specific structural characteristics. These local quality differences in the transmembrane domains (TM2-TM3 and TM5-TM6 regions) provide unique binding pockets that can be targeted by selectively designed modulators. The local structural variations in these regions, compared to other mGlu isoforms, enable the development of compounds with high selectivity for mGlu2.
3Reliability
If high potency modulators are designed with low IC50 values, then therapeutic efficacy improves, but risk of off-target effects increases
Solution Approach 1:
By using allosteric sites as intermediaries, the patent achieves high potency modulation (low IC50 values) while maintaining selectivity. The allosteric binding sites, being less conserved than orthosteric sites, provide a structural basis for high affinity binding that is specific to mGlu2. This intermediary approach allows potent modulation of mGlu2 function without the off-target effects that would result from targeting highly conserved orthosteric regions.
Data Source
AI summary
Described are 6-aryl quinazolin-4(3H)-ones as negative allosteric modulators of metabotropic glutamate receptor 2 (mGlu2), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating depression, anxiety, obsessive-compulsive disorder, cognitive disorders, Alzheimer's disease, or autism spectrum disorders in a subject.